TY - JOUR
T1 - Estimating the burden of fungal diseases in Israel
AU - Ben-Ami, Ronen
AU - Denning, David W.
N1 - Publisher Copyright:
© 2015, Israel Medical Association. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Fungal diseases affect a large proportion of the population, ranging in severity from mild superficial infections to lifethreatening invasive diseases. Estimates of disease burden are needed to inform public health policies. We estimated the incidence of fungal diseases in Israel based on published surveillance data and risk-based calculations using previously established models. Deaths associated with fungal diseases were estimated from local surveillance data (candidemia) and published reports (invasive aspergillosis). Candidemia was estimated in 649 persons/year and invasive aspergillosis in 254 persons/year; the associated mortality was 2.75 and 0.96 per 100,000 population/year, respectively. Recurrent Candida vulvovaginitis occurs in 130,440 women annually. National incidence rates of cryptococcosis, pneumocystis pneumonia and mucormycosis could not be reliably estimated. Singlecenter data-derived estimates yielded 24, 26 and 20 cases/ year, respectively. Allergic bronchopulmonary aspergillosis, asthma with fungal sensitization and allergic fungal sinusitis affect 8297 (range 2323–11,615), 14,372 (14,372–17,965) and 39,922 (15,969–183,643) persons, respectively. In Israel, candidemia and invasive aspergillosis rank high among infection-related causes of mortality. Allergic fungal diseases cause chronic or recurrent symptoms in a large population and may contribute to asthma-related hospitalization and death. These general estimates should serve as a primer for future efforts to study fungal epidemiology.
AB - Fungal diseases affect a large proportion of the population, ranging in severity from mild superficial infections to lifethreatening invasive diseases. Estimates of disease burden are needed to inform public health policies. We estimated the incidence of fungal diseases in Israel based on published surveillance data and risk-based calculations using previously established models. Deaths associated with fungal diseases were estimated from local surveillance data (candidemia) and published reports (invasive aspergillosis). Candidemia was estimated in 649 persons/year and invasive aspergillosis in 254 persons/year; the associated mortality was 2.75 and 0.96 per 100,000 population/year, respectively. Recurrent Candida vulvovaginitis occurs in 130,440 women annually. National incidence rates of cryptococcosis, pneumocystis pneumonia and mucormycosis could not be reliably estimated. Singlecenter data-derived estimates yielded 24, 26 and 20 cases/ year, respectively. Allergic bronchopulmonary aspergillosis, asthma with fungal sensitization and allergic fungal sinusitis affect 8297 (range 2323–11,615), 14,372 (14,372–17,965) and 39,922 (15,969–183,643) persons, respectively. In Israel, candidemia and invasive aspergillosis rank high among infection-related causes of mortality. Allergic fungal diseases cause chronic or recurrent symptoms in a large population and may contribute to asthma-related hospitalization and death. These general estimates should serve as a primer for future efforts to study fungal epidemiology.
KW - Allergic bronchopulmonary aspergillosis
KW - Candidiasis
KW - Epidemiology
KW - Fungal disease
KW - Invasive aspergillosis
UR - http://www.scopus.com/inward/record.url?scp=84934298266&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 26233998
AN - SCOPUS:84934298266
SN - 1565-1088
VL - 17
SP - 374
EP - 380
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 6
ER -